Sodium-glucose cotransporter 2 inhibitors for chronic kidney disease: Why, when and when not.
| Title: | Sodium-glucose cotransporter 2 inhibitors for chronic kidney disease: Why, when and when not. |
|---|---|
| Authors: | Javaid MM; FRCP, FASN, FRACP, Adjunct Clinical Associate Professor, Rural Health Mildura, Monash University, Melbourne, Vic; Affiliate Associate Professor, School of Medicine, Deakin University, Warrnambool, Vic; Staff Specialist Nephrologist and Physician, South West Healthcare, Warrnambool, Vic.; Frederick R; MBBS, Advanced Trainee General Medicine, University Hospital Geelong, Geelong, Vic.; Itrat S; MRCGP, FRACGP, General Practitioner, Your Hobart Doctor, Hobart, Tas.; Ekladious A; FRCP, FRACP, Consultant Physician, Department of General Medicine and Acute Assessment Unit, Canberra Hospital, Canberra, ACT; Clinical Associate Professor, Faculty of Health and Medical Sciences, University of Western Australia, Perth, WA; Associate Professor, ANU College of Health and Medicine, Australian National University, Canberra, ACT. |
| Source: | Australian journal of general practice [Aust J Gen Pract] 2024 Dec Supplement; Vol. 53 (12 Suppl), pp. S15-S19. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Royal Australian College of General Practitioners Country of Publication: Australia NLM ID: 101718099 Publication Model: Print Cited Medium: Internet ISSN: 2208-7958 (Electronic) NLM ISO Abbreviation: Aust J Gen Pract Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: East Melbourne, Victoria : Royal Australian College of General Practitioners, [2018]- |
| MeSH Terms: | Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use ; Sodium-Glucose Transporter 2 Inhibitors*/pharmacology ; Renal Insufficiency, Chronic*/drug therapy ; Renal Insufficiency, Chronic*/complications ; Renal Insufficiency, Chronic*/physiopathology; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/complications ; Humans ; Disease Progression |
| Abstract: | Background: Chronic kidney disease (CKD) is a significant healthcare problem. More advanced stages are associated with increased mortality, morbidity and cost. Instigating measures to slow down disease progression at an early stage can save lives, and millions of dollars of taxpayers' money.; Objective: This article aims to provide evidence-based information to general practitioners, aiding the decision to initiate sodium-glucose cotransporter 2 (SGLT2) inhibitors for CKD patients in their day-to-day practice.; Discussion: SGLT2 inhibitors have emerged as a promising and safe addition to the renin-angiotensin-aldosterone system blockers for managing CKD. Randomised controlled trials have shown that SGLT2 inhibitors effectively slow CKD progression in both early and more advanced disease stages, regardless of diabetes status. SGLT2 inhibitors can be a valuable additional treatment option for CKD management in primary care and should be considered for most CKD patients. |
| Substance Nomenclature: | 0 (Sodium-Glucose Transporter 2 Inhibitors) |
| Entry Date(s): | Date Created: 20241218 Date Completed: 20241218 Latest Revision: 20260503 |
| Update Code: | 20260503 |
| DOI: | 10.31128/AJGP-11-23-7041 |
| PMID: | 39693744 |
| Database: | MEDLINE |
Journal Article